Ablation of the microglial protein DOCK2 reduces amyloid burden in a mouse model of Alzheimer's disease

Patrick J. Cimino, Yue Yang, Xianwu Li, Jake F. Hemingway, Makenzie K. Cherne, Shawn B. Khademi, Yoshinori Fukui, Kathleen S. Montine, Thomas J. Montine, C. Dirk Keene

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Alzheimer's disease (AD) neuropathology is characterized by innate immune activation primarily through prostaglandin E2 (PGE2) signaling. Dedicator of cytokinesis 2 (DOCK2) is a guanyl nucleotide exchange factor expressed exclusively in microglia in the brain and is regulated by PGE2 receptor EP2. DOCK2 modulates microglia cytokine secretion, phagocytosis, and paracrine neurotoxicity. EP2 ablation in experimental AD results in reduced oxidative damage and amyloid beta (Aβ) burden. This discovery led us to hypothesize that genetic ablation of DOCK2 would replicate the anti-Aβ effects of loss of EP2 in experimental AD. To test this hypothesis, we crossed mice that lacked DOCK2 (DOCK2-/-), were hemizygous for DOCK2 (DOCK2+/-), or that expressed two DOCK2 genes (DOCK2+/+) with APPswe-PS1δe9 mice (a model of AD). While we found no DOCK2-dependent differences in cortex or in hippocampal microglia density or morphology in APPswe-PS1δe9 mice, cerebral cortical and hippocampal Aβ plaque area and size were significantly reduced in 10-month-old APPswe-PS1δe9/DOCK2-/- mice compared with APPswe-PS1δe9/DOCK2+/+ controls. DOCK2 hemizygous APPswe-PS1δe9 mice had intermediate Aβ plaque levels. Interestingly, soluble Aβ42 was not significantly different among the three genotypes, suggesting the effects were mediated specifically in fibrillar Aβ. In combination with earlier cell culture results, our in vivo results presented here suggest DOCK2 contributes to Aβ plaque burden via regulation of microglial innate immune function and may represent a novel therapeutic target for AD.

Original languageEnglish
Pages (from-to)366-371
Number of pages6
JournalExperimental and Molecular Pathology
Volume94
Issue number2
DOIs
Publication statusPublished - Apr 1 2013

Fingerprint

Cytokinesis
Ablation
Amyloid
Alzheimer Disease
Proteins
Dinoprostone
Microglia
Cell culture
Brain
Nucleotides
Genes
Chemical activation
Cytokines
Prostaglandin Receptors
Phagocytosis

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry
  • Molecular Biology
  • Pathology and Forensic Medicine

Cite this

Cimino, P. J., Yang, Y., Li, X., Hemingway, J. F., Cherne, M. K., Khademi, S. B., ... Keene, C. D. (2013). Ablation of the microglial protein DOCK2 reduces amyloid burden in a mouse model of Alzheimer's disease. Experimental and Molecular Pathology, 94(2), 366-371. https://doi.org/10.1016/j.yexmp.2013.01.002

Ablation of the microglial protein DOCK2 reduces amyloid burden in a mouse model of Alzheimer's disease. / Cimino, Patrick J.; Yang, Yue; Li, Xianwu; Hemingway, Jake F.; Cherne, Makenzie K.; Khademi, Shawn B.; Fukui, Yoshinori; Montine, Kathleen S.; Montine, Thomas J.; Keene, C. Dirk.

In: Experimental and Molecular Pathology, Vol. 94, No. 2, 01.04.2013, p. 366-371.

Research output: Contribution to journalArticle

Cimino, PJ, Yang, Y, Li, X, Hemingway, JF, Cherne, MK, Khademi, SB, Fukui, Y, Montine, KS, Montine, TJ & Keene, CD 2013, 'Ablation of the microglial protein DOCK2 reduces amyloid burden in a mouse model of Alzheimer's disease', Experimental and Molecular Pathology, vol. 94, no. 2, pp. 366-371. https://doi.org/10.1016/j.yexmp.2013.01.002
Cimino, Patrick J. ; Yang, Yue ; Li, Xianwu ; Hemingway, Jake F. ; Cherne, Makenzie K. ; Khademi, Shawn B. ; Fukui, Yoshinori ; Montine, Kathleen S. ; Montine, Thomas J. ; Keene, C. Dirk. / Ablation of the microglial protein DOCK2 reduces amyloid burden in a mouse model of Alzheimer's disease. In: Experimental and Molecular Pathology. 2013 ; Vol. 94, No. 2. pp. 366-371.
@article{c464e8ce18f54582863c9c8bce1dd669,
title = "Ablation of the microglial protein DOCK2 reduces amyloid burden in a mouse model of Alzheimer's disease",
abstract = "Alzheimer's disease (AD) neuropathology is characterized by innate immune activation primarily through prostaglandin E2 (PGE2) signaling. Dedicator of cytokinesis 2 (DOCK2) is a guanyl nucleotide exchange factor expressed exclusively in microglia in the brain and is regulated by PGE2 receptor EP2. DOCK2 modulates microglia cytokine secretion, phagocytosis, and paracrine neurotoxicity. EP2 ablation in experimental AD results in reduced oxidative damage and amyloid beta (Aβ) burden. This discovery led us to hypothesize that genetic ablation of DOCK2 would replicate the anti-Aβ effects of loss of EP2 in experimental AD. To test this hypothesis, we crossed mice that lacked DOCK2 (DOCK2-/-), were hemizygous for DOCK2 (DOCK2+/-), or that expressed two DOCK2 genes (DOCK2+/+) with APPswe-PS1δe9 mice (a model of AD). While we found no DOCK2-dependent differences in cortex or in hippocampal microglia density or morphology in APPswe-PS1δe9 mice, cerebral cortical and hippocampal Aβ plaque area and size were significantly reduced in 10-month-old APPswe-PS1δe9/DOCK2-/- mice compared with APPswe-PS1δe9/DOCK2+/+ controls. DOCK2 hemizygous APPswe-PS1δe9 mice had intermediate Aβ plaque levels. Interestingly, soluble Aβ42 was not significantly different among the three genotypes, suggesting the effects were mediated specifically in fibrillar Aβ. In combination with earlier cell culture results, our in vivo results presented here suggest DOCK2 contributes to Aβ plaque burden via regulation of microglial innate immune function and may represent a novel therapeutic target for AD.",
author = "Cimino, {Patrick J.} and Yue Yang and Xianwu Li and Hemingway, {Jake F.} and Cherne, {Makenzie K.} and Khademi, {Shawn B.} and Yoshinori Fukui and Montine, {Kathleen S.} and Montine, {Thomas J.} and Keene, {C. Dirk}",
year = "2013",
month = "4",
day = "1",
doi = "10.1016/j.yexmp.2013.01.002",
language = "English",
volume = "94",
pages = "366--371",
journal = "Experimental and Molecular Pathology",
issn = "0014-4800",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Ablation of the microglial protein DOCK2 reduces amyloid burden in a mouse model of Alzheimer's disease

AU - Cimino, Patrick J.

AU - Yang, Yue

AU - Li, Xianwu

AU - Hemingway, Jake F.

AU - Cherne, Makenzie K.

AU - Khademi, Shawn B.

AU - Fukui, Yoshinori

AU - Montine, Kathleen S.

AU - Montine, Thomas J.

AU - Keene, C. Dirk

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Alzheimer's disease (AD) neuropathology is characterized by innate immune activation primarily through prostaglandin E2 (PGE2) signaling. Dedicator of cytokinesis 2 (DOCK2) is a guanyl nucleotide exchange factor expressed exclusively in microglia in the brain and is regulated by PGE2 receptor EP2. DOCK2 modulates microglia cytokine secretion, phagocytosis, and paracrine neurotoxicity. EP2 ablation in experimental AD results in reduced oxidative damage and amyloid beta (Aβ) burden. This discovery led us to hypothesize that genetic ablation of DOCK2 would replicate the anti-Aβ effects of loss of EP2 in experimental AD. To test this hypothesis, we crossed mice that lacked DOCK2 (DOCK2-/-), were hemizygous for DOCK2 (DOCK2+/-), or that expressed two DOCK2 genes (DOCK2+/+) with APPswe-PS1δe9 mice (a model of AD). While we found no DOCK2-dependent differences in cortex or in hippocampal microglia density or morphology in APPswe-PS1δe9 mice, cerebral cortical and hippocampal Aβ plaque area and size were significantly reduced in 10-month-old APPswe-PS1δe9/DOCK2-/- mice compared with APPswe-PS1δe9/DOCK2+/+ controls. DOCK2 hemizygous APPswe-PS1δe9 mice had intermediate Aβ plaque levels. Interestingly, soluble Aβ42 was not significantly different among the three genotypes, suggesting the effects were mediated specifically in fibrillar Aβ. In combination with earlier cell culture results, our in vivo results presented here suggest DOCK2 contributes to Aβ plaque burden via regulation of microglial innate immune function and may represent a novel therapeutic target for AD.

AB - Alzheimer's disease (AD) neuropathology is characterized by innate immune activation primarily through prostaglandin E2 (PGE2) signaling. Dedicator of cytokinesis 2 (DOCK2) is a guanyl nucleotide exchange factor expressed exclusively in microglia in the brain and is regulated by PGE2 receptor EP2. DOCK2 modulates microglia cytokine secretion, phagocytosis, and paracrine neurotoxicity. EP2 ablation in experimental AD results in reduced oxidative damage and amyloid beta (Aβ) burden. This discovery led us to hypothesize that genetic ablation of DOCK2 would replicate the anti-Aβ effects of loss of EP2 in experimental AD. To test this hypothesis, we crossed mice that lacked DOCK2 (DOCK2-/-), were hemizygous for DOCK2 (DOCK2+/-), or that expressed two DOCK2 genes (DOCK2+/+) with APPswe-PS1δe9 mice (a model of AD). While we found no DOCK2-dependent differences in cortex or in hippocampal microglia density or morphology in APPswe-PS1δe9 mice, cerebral cortical and hippocampal Aβ plaque area and size were significantly reduced in 10-month-old APPswe-PS1δe9/DOCK2-/- mice compared with APPswe-PS1δe9/DOCK2+/+ controls. DOCK2 hemizygous APPswe-PS1δe9 mice had intermediate Aβ plaque levels. Interestingly, soluble Aβ42 was not significantly different among the three genotypes, suggesting the effects were mediated specifically in fibrillar Aβ. In combination with earlier cell culture results, our in vivo results presented here suggest DOCK2 contributes to Aβ plaque burden via regulation of microglial innate immune function and may represent a novel therapeutic target for AD.

UR - http://www.scopus.com/inward/record.url?scp=84873433241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873433241&partnerID=8YFLogxK

U2 - 10.1016/j.yexmp.2013.01.002

DO - 10.1016/j.yexmp.2013.01.002

M3 - Article

C2 - 23318649

AN - SCOPUS:84873433241

VL - 94

SP - 366

EP - 371

JO - Experimental and Molecular Pathology

JF - Experimental and Molecular Pathology

SN - 0014-4800

IS - 2

ER -